Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Holding ADCT?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.42Last Year’s EPS
-$1.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -38.75%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ADC Therapeutics' performance. While there are significant achievements in revenue growth, financial stability, and clinical progress, challenges remain with competition in the market and the discontinuation of a solid tumor program. Financial losses continue, but the company's disciplined financial management and strategic focus on ZYNLONTA and promising trials offer a positive outlook.Company Guidance
During the ADC Therapeutics Q3 2024 earnings call, the company provided detailed guidance on several key metrics and strategic initiatives. Net product revenues for ZYNLONTA were reported at $18 million for the third quarter, contributing to a year-to-date total of $52.9 million. The company highlighted its strong financial position with $274.3 million in cash and cash equivalents, expected to fund operations into mid-2026. ADC Therapeutics remains focused on expanding ZYNLONTA's use beyond its current indication, with enrollment in the LOTIS-5 Phase III study nearing completion and data from LOTIS-7's dose expansion expected in December 2024. Additionally, the company discontinued the ADCT-601 program, while advancing its exatecan-based platform for solid tumors. On a non-GAAP basis, the adjusted net loss stood at $29.4 million, reflecting higher revenues and reduced operating expenses year-over-year. Overall, the call underscored ADC Therapeutics' commitment to strategic capital allocation, commercial execution, and advancing its clinical pipeline.Increased Net Product Revenues
Third quarter net product revenues increased to $18 million, bringing year-to-date ZYNLONTA revenues to $52.9 million, showing growth in a competitive market.
Strong Financial Position
The company ended the third quarter with $274.3 million in cash and cash equivalents, expected to fund operations into mid-2026.
Progress in Clinical Trials
Enrollment in the LOTIS-5 Phase III study nearing completion, with data expected by the end of 2025, and interim data from LOTIS-7 anticipated in December.
Potential Expansion Opportunities
Investigator-initiated trials for ZYNLONTA in indolent lymphomas showing promising early data, with presentations scheduled at the ASH meeting.
Disciplined Capital Allocation
Operating expenses decreased by 12% year-over-year on a non-GAAP basis, reflecting a disciplined approach to capital allocation.
---
ADCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.20 | $2.93 | -8.44% |
| Aug 06, 2024 | $2.87 | $2.92 | +1.74% |
| May 06, 2024 | $4.90 | $4.45 | -9.18% |
| Mar 13, 2024 | $4.45 | $3.90 | -12.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ADC Therapeutics Ltd (ADCT) report earnings?
ADC Therapeutics Ltd (ADCT) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is ADC Therapeutics Ltd (ADCT) earnings time?
ADC Therapeutics Ltd (ADCT) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADCT EPS forecast?
ADCT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.42.
---